CX1739 has similar pharmacological effects and favorable safety profile to older "Type II" ampakines such asCX516 andCX717, but with higher potency and improved bioavailability, unlike "Type I" ampakines such asCX614 which have been found to produceneurotoxicity at high doses.[6]
As with related ampakine compounds CX1739 hasnootropic (memory enhancment) effects,[1] and was originally investigated for applications such as treatment ofADHD anddementia, but in the course of testing it was found to be effective as arespiratory stimulant and for facilitating nerve repair, so recent research has focused on potential use for conditions such assleep apnoea and recovery fromspinal cord injury.[7][8]
^abRadin DP, Lippa A, Rana S, Fuller DD, Smith JL, Cerne R, et al. (2025). "Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today".Pharmacology, Biochemistry, and Behavior.248 173967.doi:10.1016/j.pbb.2025.173967.PMC 11849398.PMID39894310.
^Xiao D, Xie F, Xu X, Zhou X (2020). "The Impact and Mechanism of Ampakine CX1739 on Protection Against Respiratory Depression in Rats".Future Medicinal Chemistry.12 (23):2093–2104.doi:10.4155/fmc-2020-0256.PMID33030058.
^Ren J, Ding X, Greer JJ (2015). "Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats".American Journal of Respiratory and Critical Care Medicine.191 (6):704–710.doi:10.1164/rccm.201410-1898OC.PMID25594679.
^Radin DP, Zhong S, Cerne R, Witkin JM, Lippa A (2024). "High Impact AMPAkines Induce a Gq-Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines".Synapse.78 (5) e22310. New York, N.Y.doi:10.1002/syn.22310.PMID39304968.
Radin DP, Cerne R, Witkin JM, Lippa A (2025). "Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers".Clinical Pharmacology in Drug Development.14 (1):50–58.doi:10.1002/cpdd.1475.PMID39302241.
